News

Filter

Breakthrough designation for B-MS/AbbVie’s MM drug elotuzumab

19-05-2014

The US Food and Drug Administration has granted elotuzumab, an investigational humanized monoclonal antibody…

AbbVieBristol-Myers SquibbelotuzumabOncologyPharmaceuticalRegulationUSA

Rise in infections means hepatitis C market is expected to peak at $15.5 billion in 2022

27-08-2013

The hepatitis C market is forecast to increase by a massive 230% in the next nine years, according to…

AbbVieAntibiotics and Infectious diseasesBristol-Myers SquibbGilead SciencesGlobalJohnson & JohnsonMarkets & MarketingPharmaceuticalsofosbuvir

Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib

16-06-2013

Among presentations over the weekend at the Congress of European Hematology Association (EHA) being held…

AbbVieBristol-Myers SquibbelotuzumabibrutinibIncyteJakaviJanssenJohnson & JohnsonNovartisOncologyPharmaceuticalPharmacyclicsResearch

Bristol-Myers Orencia equals Humira in head-to-head AMPLE RA study

12-06-2013

US drug major Bristol-Myers Squibb (NYSE: BMY) has announced the results of year two data from AMPLE…

AbbVieAnti-Arthritics/RheumaticsBristol-Myers SquibbHumiraOrenciaPharmaceuticalResearch

Highlights of presentations from Bristol-Myers, J&J, Gilead and AbbVie at EASL meeting

24-04-2013

Among a number of drug and biotech majors planning to present at the 2013 annual meeting of the European…

AbbVieAnti-viralsasunaprevirBiotechnologyBristol-Myers SquibbdaclatasvirGilead SciencesJohnson & JohnsonPharmaceuticalResearchsimeprevirsofosbuvir

COMPANY SPOTLIGHT

Menarini

Back to top